Comprehensive HF care
The treatment of patients with HFrEF is underpinned by large-scale randomized clinical trials, as reflected in the guidelines of leading heart failure associations.
These guidelines and consensus statements advocate for drugs and devices as cornerstones in HF disease management, alongside personalized care and patient engagement.
However, despite guideline recommendations and available evidence, treatment implementation remains inadequate.
This includes both drugs and devices that demonstrated a positive impact on morbidity and mortality.
To enhance HF disease management, two crucial aspects must be considered:
- Adopting a multidisciplinary team approach
- Integrating all components of HF care, including medications and interventions, as well as lifestyle adjustments and monitoring strategies
References
- McDonagh TA et al. Eur Heart J. 2021;42:3599-726;
- Heidenreich PA et al. J Am Coll Cardiol. 2022;79:e263-e421;
- Tsutsui H et al. Circ J. 2019;83:2084-184;
- Ezekowitz JA et al. Can J Cardiol. 2017;33:1342-433;
- Bozkurt B et al. Nat Rev Cardiol. 2024;21:545-55;
- Mullens W et al. Eur J Heart Fail. 2024;26:483-501
Right implementation of both medical therapy &
devices for the Right patients at the Right time
Right implementation of both medical therapy & devices for the Right patients at the Right time
